Therapeutic treatments targeting communication between angiogenic and immune microenvironments in thyroid cancers
{{output}}
Thyroid cancer treatment has recently been revolutionized by the introduction of specific targeted therapies (e.g. BRAFV600E or highly selective RET inhibitors), anti-angiogenic agents (e.g. tyrosine kinase inhibitors (TKIs)) and immune checkpoint inhibitors, ... ...
